Asklepios BioPharmaceutical, Inc (AskBio): AskBio Names Mansuo Shannon Chief Scientific Officer finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Gene therapy legend R. Jude Samulski, Ph.D., co-founder and chief scientific officer of Asklepios BioPharmaceutical (AskBio) since the company was established in 2001, is leaving the CSO job but remaining on the company board.AskBio announced that Mansuo Shannon, Ph.D., becomes CSO effective today. Shannon joins AskBio from Prevail Therapeutics, a wholly owned subsidiary of Eli Lilly and Company, where she also served as CSO.
First Patient Randomized in AskBio Phase II Gene Therapy Trial for Congestive Heart Failure streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
AB-1002 is an investigational gene therapy for the treatment of adults with non-ischemic cardiomyopathy and New York Heart Association (NYHA) Class III heart failure symptoms1GenePHIT is a clinical trial to evaluate the safety and efficacy of the one-time administration of AB-1002 and will include the largest number.